Leerink Partnrs Has Negative Outlook of ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Leerink Partnrs decreased their FY2024 EPS estimates for Alnylam Pharmaceuticals in a report issued on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($2.48) per share for the year, down from their previous forecast of ($1.74). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.94) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at $0.49 EPS.

Several other research analysts also recently weighed in on the stock. Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Bank of America increased their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $266.54 on Thursday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The firm’s 50-day moving average price is $245.91 and its 200-day moving average price is $259.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 EPS.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,122 shares of company stock valued at $2,540,455. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Souders Financial Advisors increased its position in Alnylam Pharmaceuticals by 1.0% in the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 36 shares during the period. Huntington National Bank raised its stake in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. SYM FINANCIAL Corp raised its stake in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 55 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 57 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Alnylam Pharmaceuticals by 0.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock worth $1,532,000 after acquiring an additional 58 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.